Exactech Breaks Ground in Foot and Ankle Market with Successful First Surgery
October 13 2016 - 9:00AM
Business Wire
Product Expansion Capitalizes on Successful
Extremities Business
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products for extremities, hip, knee, and
spine, announced today a successful first surgery using its new
Vantage® Total Ankle System, the newest addition to the Exactech
extremities product line and its first product in the foot and
ankle market.
Orthopaedic surgeons Mark Easley, MD, and James Nunley, MD, of
Duke University, performed the first case with the ankle implant in
Durham, N.C. “The surgical team and I were pleased that the Vantage
Total Ankle replacement went exactly according to plan,” Easley
said. “After several years of thoughtful development and design,
the anatomic implants, practical instrumentation and relatively
simple technique performed as they were designed. Based on
proprietary anatomic data, the Exactech Vantage Total Ankle team of
surgeons and engineers developed an innovative total ankle design
that features both anatomic talar and tibial components.”
Easley also added, “The technique, with its favorable tibial and
talar bone preparation which was clearly designed with minimal bone
resection in mind, affords optimal support for the anatomically
shaped implants. The Vantage Total Ankle has a reproducible and
surgeon-friendly technique.”
Exactech Vice President of Extremities Marketing Darin Johnson
said, “We had the privilege to design this product with some of the
best thought leaders in the world who have dedicated their careers
to the treatment of the ankle. Our team is proud to be a part of
successfully improving the surgical outcome for one patient and
laying the foundation for many, many more in the years to come.
This marks a strategic expansion into the foot and ankle market
where we will leverage Exactech’s founding principle of solving
clinical challenges in collaboration with surgeons in order to
improve the lives of patients. It is an exciting time.”
This ankle system represents years of collaboration among
Exactech and a design team of esteemed surgeons including: James
Nunley, MD; James DeOrio, MD; and Mark Easley, MD, of Duke
University in Durham, N.C.; and Victor Valderrabano, MD, PhD, of
Swiss Ortho Center of Schmerzklinik Basel in Basel,
Switzerland.
Full market availability of the Vantage Total Ankle System in
the United States is planned for 2017.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005213/en/
Exactech, Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance & Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorMedia contactPriscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024